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Introduction
Intraocular pressure is currently the sole modifiable risk factor and predictive measure for glaucoma 1,2 , 3,4 ( Supplementary Figure S1 ).Genome-wide association studies(GWAS) have commonly used genetic associations to this endophenotype that exhibits high genetic correlation (rg = 0.71) to glaucoma, as an approach to prioritize genetic variants likely to contribute to disease risk 5 . A total of 53 independent loci have been unequivocally implicated in glaucoma 5 . For these discoveries, like most GWAS results, it has proven challenging to infer the functional consequences of common variant associations beyond cases where protein-altering variants have been directly implicated. Protein-altering variants, generally the strongest-acting genetic variants in medical genetics, include nonsynonymous substitutions and protein-truncating variants, and understanding their functional consequences provides insight into the therapeutic effects of inhibiting or down-regulating the gene in which they reside 6 . Thus, identifying protein-altering variants that confer protection from disease holds particular promise for identifying therapeutic targets.
Here we leverage two population biobanks that provide complementarity for glaucoma gene discovery. First, UK Biobank has obtained intraocular pressure (IOP) measurements in approximately 128,000 individuals in addition to case-control status for glaucoma from hospital in-patient and verbal questionnaire data in over 500,000 individuals 7, 8 . Second, FinnGen has directly genotyped and aggregated disease outcomes in over 135,000 individuals from Finland, an isolated population with recent bottlenecks that offers an unprecedented advantage for studying rare variants in complex diseases 9 . With clinic-based recruitment focused on several areas including ophthalmology, and with 32.4% of the collection above age 70, FinnGen is particularly well-powered for aging-associated endpoints. We therefore conduct targeted association analysis with IOP in UK Biobank (N = 81,534) to identify protein-altering variants that reduce IOP, and test whether those variants, or others in the same genes, also confer protection to glaucoma in FinnGen (5, 177 cases and 130,461 controls) and UK Biobank (4,269 cases and 251,355 controls not included in the IOP sample). Analysis of an allelic series of protein-altering variants in ANGPTL7 in 9,446 glaucoma patients and over 350,000 controls identifies a significant lowering effect on IOP and protective association with glaucoma. By analyzing putative loss-of-function variants, we find concordant effect directions with the nonsynonymous substitutions, suggesting that the protective mechanism may reside in the loss of gene function.
We conducted protein-altering variant association analysis with IOP, as measured via Goldmann-correlated tonometry, in 81,527 British individuals in UK Biobank dataset (Methods) 10 . Across 41,632 rare (0.01 % < MAF < 1%) protein-altering variants outside of the MHC region with genotyping array data in UK Biobank, we used a generalized linear model implemented in PLINK 11 to scan for variants with IOP-lowering effects. We identified one protein-altering variant significantly associated with lower IOP below a Bonferroni-corrected P value < 1.0x10 -6 , a nonsynonymous substitution (p.Gln175His) in ANGPTL7 ( P = 1.47x10 -13 , = β -0.200 SD 95% CI: [-0.253, -0.147], -0.73 mHg for heterozygotes, -2.96 mmHg for homozygotes, Table 1 Based on this finding, we assessed whether any additional rare variant associations in ANGPTL7 were present. We found three additional independent rare protein-altering variants in ANGPTL7 (MAF < 0.25%) including a premature stop-gain allele (p.Arg177Ter). Collectively, these three variants showed a marginally significant association with lower IOP ( P = 0.0023, Table 1 ), with the stop-gain allele p.Arg177Ter also showing a marginally significant effect on its own ( P = 0.038). Genotyping intensity plots and the concordance of genotype calls from array and whole-exome sequencing data were manually inspected to ensure high quality and consistent genotyping ( Supplementary Figures S3, Supplementary Table S1 , Methods ) and alleles were confirmed to be independent (pairwise r 2 < 10 -4 for each, Supplementary Table  S2 , Methods ). Using inverse variance method, the combined effect of those four variants are estimated to be -0.19 ( [95% CI: -0.23 --0.14] SD, P = 3.4x10 -16 ; -0.67 mmHg [95% CI: -0.85 --0.49], Supplementary Figures S4, Supplementary Table S3 -4, Methods ).
Given these findings, we next asked whether any of these putative IOP-lowering genetic variants showed effects consistent with reducing glaucoma risk in an independent set of British individuals that do not have IOP measures (4,269 cases and 251,355 controls). For p.Gln175His in ANGPTL7 , we estimated that the variant lowers glaucoma risk by 34% ( P = 0.00543; OR = 0.66 [95% CI: 0.366 -0.954]). The three additional protein-altering variants did not significantly confer protection against glaucoma (burden test P = 0.55), although we expect this to be a result of limited power in the binary case-control setting. 
Independent Finnish-enriched missense allele in ANGPTL7
We then sought evidence from the FinnGen dataset that either the same or novel Finnish-enriched protein-altering variants would confirm the association of ANGPTL7 with protection from glaucoma. This additional ANGPTL7 association data, obtained in 5,177 glaucoma patients and 130,461 controls, provided strong support that protein-altering variants in ANGPTL7 protect against glaucoma (case definitions described in Supplementary Table S5 ). Specifically, we found that the p.Gln175His substitution has nominal evidence of association ( P = 0.031, OR = 0.49) despite the variant only being present at a minor allele frequency of 0.1% in this Finnish cohort (8-fold depleted compared to UK Biobank). The remaining protein-altering 4/34 variants in ANGPTL7 tested in UK Biobank were not found in the FinnGen dataset. Confirmation of an ANGPTL7 effect on glaucoma risk was seen in data from an independent Finnish-specific protein-altering nonsynonymous substitution, p.Arg220Cys, which was strongly associated with protection from glaucoma ( P = 1.0x10 -9 , OR = 0.72 [95% CI: 0.64 -0.81], Supplementary Figure S5 ). Of note, this observation is advantaged by the property that p.Arg220Cys is found at a greater than 50-fold increased frequency in Finland compared with other populations 12 , reinforcing the value of isolated, bottlenecked populations in which the allele frequency spectrum is intensely concentrated on the minority of variants passing through the bottleneck.
While registry-based diagnoses in FinnGen do not yet contain detailed ophthalmologic records, a subset of 2695 glaucoma patients had been recorded as having primary open-angle glaucoma (POAG). In this sub-group a stronger effect was observed (OR=0.68) versus those glaucoma cases without a definitive record of POAG (OR=0.77), reminiscent of the stronger risk effects seen at the myocilin ( MYOC ) gene and other established genes in the POAG subgroup. Given the Finnish enrichment of the known strong glaucoma risk allele, p.Gln368Ter, in MYOC (MAF in Finland = 0.3%, MAF in Non-Finnish European = 0.16%, reference sequence: NM_00026), we next asked whether carriers have risk reduced if they carry ANGPTL7 p.Arg220Cys. In FinnGen, we estimate that 7.7% of individuals carriers for MYOC p.Gln368Ter variant are POAG cases in comparison to 2% for non-carriers. In the presence of ANGPTL7 p.Arg220Cys, only 1.3% of individuals are POAG cases, and only 1 of 70 (1.4%) who carry both MYOC risk and ANGPTL7 protective variants were POAG cases ( Supplementary Table S6 ). This suggests ANGPTL7 protection extends to the MYOC risk group but the small counts preclude any definitive statement regarding interaction -given the limited number of double-carriers, larger case-control series are needed to refine our understanding as to whether ANGPTL7 p.Arg220Cys variant modifies the glaucoma risk conferred by p.Gln368Ter in MYOC .
Access to genotype data in over 300,000 individuals from the UK and 135,000 from the Finnish group enabled us to identify rare protein-altering homozygotes. In UK Biobank we found 28 individuals homozygous for the 175His allele, consistent with Hardy-Weinberg expectation (n=22.6), where we estimated a 2.96 mm Hg drop in IOP compared to the mean IOP levels. Furthermore, the oldest reached the age of 80 and one of the 28 died (age 65). In FinnGen we found 268 individuals homozygous for the 220C allele, the oldest reached the age of 98, with no depletion of homozygotes compared with Hardy-Weinberg equilibrium expectation. There was no significant association of the homozygous genotype with a decreased lifespan. Together this indicates that having two copies with 175His or 220Cys in ANGPTL7 is compatible with normal lifespan. To assess the potential impacts of those protein-truncating variants on reproductive fitness we assessed the association of p.Gln175His with the number of live births and number of children fathered and found no significant association ( P > 0.05/4, Supplementary Table S7 ). Hence, we did not find any severe medical consequences that would be of obvious concern in developing a therapeutic to mimic the effect of these alleles. The combined significance of ANGPTL7 protein-altering variants across more than 435,000 samples tested is P = 3.4x10 -16 for IOP and P = 1.9x10 -11 for glaucoma using inverse-variance weighted method ( Supplementary Figure S6 ).
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Transcript and protein expression
ANGPTL7 , a five-exon protein-coding gene, encodes the Angiopoietin-related protein 7, which is expressed in several human tissues including the trabecular meshwork, cornea and retina [13] [14] [15] .
Recently, ANGPTL7 overexpression in primary human trabecular meshwork cells was found to alter the expression of relevant trabecular meshwork proteins of the extracellular matrix, including fibronectin, collagens type I, IV, and V, myocilin, versican, and MMP1, and ANGPTL7 protein was increased as the disease progressed in POAG beagle dogs 13 . We examined proteomics expression data in normal tissues and cell lines from ProteomicsDB and MOPED 16, 17 and found vitreous humor tissue-specific expression of ANGPTL7 (log10 ppm = 1, Supplementary Figure S7 ). These data suggest that the eye is the relevant tissue type in understanding the functional consequences of the variants discovered in this study. Further work is dissecting the role of ANGPL7 in all possible cell types in the eye is warranted.
Discussion
This study establishes strong genetic evidence for the involvement of ANGPTL7 in glaucoma risk in which a powerful allelic series, including all low-frequency nonsynonymous substitutions and a single premature stop-gain substitution, is conclusively associated with reduced disease risk and endophenotype-lowering effects. Increasing evidence is associating ANGPTL proteins to cardiometabolic phenotypes [18] [19] [20] [21] [22] . Although it has been recently proposed that ANGPTL7 levels are increased in obesity and reduced after physical exercise, we do not observe any evidence of genetic association in either UK Biobank or FinnGen to support this hypothesis 23 . In the context of the other established variants in glaucoma, including the protein-truncating variants in MYOC , p.Gln175His and the 57-fold Finnish enriched p.Arg220Cys variant in ANGPTL7 exert a comparable protective effect. Because of the strong protective effect associated with the ANGPTL7 coding variants, studies of ANGPTL7 inhibition and the specific action of these variant proteins should be useful in understanding the mechanism by which protection to glaucoma disease occurs and whether this reveals a promising therapeutic opportunity similar to that which has been realized from the examples of PCSK9, APOC3 and cardiovascular disease 24-26 . The phenotype and longevity profile of ANGPTL7 homozygotes suggest that this is likely to be a safe strategy for therapeutic intervention. 
Methods
Genome-wide association analysis in UK Biobank
For British individuals (n = 337,151) in UK Biobank as described elsewhere 8 , we applied genome-wide association analysis for directly genotyped variants were applied to Goldmann-correlated intraocular pressure described more detailed earlier 10 (right, UK Biobank Field ID 5255, Global Biobank Engine phenotype ID: INI5255) and glaucoma (Global Biobank Engine phenotype ID: HC276, which is previously defined as a part of "high confidence" disease outcome phenotypes by combining disease diagnoses from the UK National Health Service Hospital Episode Statistics with self-reported diagnoses questionnaire 8 ), using generalized linear model association analysis implemented in PLINK v2.00aLM (2 April 2019) with age, sex, types of genotyping array, and the first 4 genotype principal components as described elsewhere 11, 27 .
Genotyping quality control in UK Biobank
Manual inspection of intensity plots
For the identified rare (0.01 % < MAF < 1%) protein-altering variants in ANGPTL7 (reference sequence: NM_021146), we generated and inspected intensity plots with McCarthy Group's ScatterShot using "UKB -All Participants" module 28 .
Variant-calling consistency analysis
For individuals with whole-exome sequencing data (n = 49,960), we extracted the genotype calls of coding variants in ANGPTL7 using PLINK v2.00aLM (2 April 2019) and compared the consistency between array-genotyped dataset and whole-exome sequencing dataset 11, 29 .
Independence analysis of alleles Pairwise r 2 computation within British individuals in UK Biobank
We computed pairwise r 2 for the identified rare protein-altering variants in ANGPTL7 within British individuals in UK Biobank using PLINK v1.90b6.7 64-bit (2 Dec 2018) with --ld <variant_ID_1> <variant_ID_1> hwe-midp subcommand 11 . 
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Homozygous carrier analysis
For UK Biobank British individuals, we extracted the genotype calls with PLINK v2.00aLM (2 April 2019) and identified homozygous carrier of 175H allele 11 . We examined the year of birth (UK Biobank Field ID 34) and age at death (UK Biobank Field ID 40007) 7 .
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